A correlation between the expression of ERCC1 and resistance to platinum compounds has been consistently suggested in patients with advanced-stage gastric, ovarian, colorectal, esophageal and non small-cell lung cancer [Altaha et al. 2004; Dabholkar et al. 1992; Dabholkar et al. 1994; Langer et al. 2005; Joshi et al. 2005; Reed et al. 2000; Metzger et al. 1998; Lord et al. 2002; Rosell et al. 2002; Shirota et al. 2001; Warnecke-Eberz et al. 2004]. Here, ERCC1 is linked to non-small cell lung carcinoma.